1. Home
  2. XPEL vs VERA Comparison

XPEL vs VERA Comparison

Compare XPEL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XPEL Inc.

XPEL

XPEL Inc.

HOLD

Current Price

$51.48

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$43.59

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XPEL
VERA
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
3.4B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
XPEL
VERA
Price
$51.48
$43.59
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$76.60
AVG Volume (30 Days)
197.4K
1.1M
Earning Date
02-25-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.69
N/A
Revenue
$461,460,000.00
N/A
Revenue This Year
$16.20
N/A
Revenue Next Year
$11.28
N/A
P/E Ratio
$30.75
N/A
Revenue Growth
10.29
N/A
52 Week Low
$24.25
$18.53
52 Week High
$55.84
$56.05

Technical Indicators

Market Signals
Indicator
XPEL
VERA
Relative Strength Index (RSI) 48.94 42.76
Support Level $51.32 $40.87
Resistance Level $54.32 $45.51
Average True Range (ATR) 1.74 2.18
MACD -0.37 -0.67
Stochastic Oscillator 25.34 22.10

Price Performance

Historical Comparison
XPEL
VERA

About XPEL XPEL Inc.

XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: